403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
ARC Medical Inc. Completes USD $3 Million Financing To Advance Surgical Adhesion Clinical Trials
(MENAFN- EIN Presswire)
ARC Medical Inc. (ARC), a leader in surgical adhesion prevention, today announced the successful completion of the Company's latest financing, securing USD $3 million.“ARC's fundraising reaffirms investor confidence in our JOCOATTM and IPCOATTM liquid medical devices, in clinical development for the prevention of orthopedic and gynecological & abdominal surgical adhesions, respectively,” stated ARC's CEO, Dr. Chris Springate.
Surgical adhesions are the most common complication of many types of surgeries and are abnormal, fibrous bands of scar tissue that form inside the body between tissues.
ARC announced that funds from the financing will support two new clinical trials to further demonstrate the efficacy and safety of JOCOATTM and IPCOATTM:
JOCOATTM Orthopedic Clinical Trial: Led by Prof. Dr. Robert Litchfield, ARC's Chief Medical Officer and an experienced orthopedic surgery principal investigator, the company's JOCOATTM device will be evaluated in a clinical trial with 20 patients undergoing knee surgery for anterior cruciate ligament (ACL) repair.
IPCOATTM Gynecological Clinical Trial: Led by Prof. Dr. Rudy De Wilde, a worldwide key opinion leader in gynecological surgical adhesion reduction, ARC's IPCOATTM device will be evaluated in a clinical trial with 20 patients undergoing gynecological surgery for the treatment of endometriosis.
In addition to the clinical trials, the funding provides additional runway for ARC to continue current discussions towards a Japanese partnership agreement.
Over 11 million patients in the US and 1 million patients in Japan undergo orthopedic, gynecological and abdominal surgeries that may benefit from the use of ARC's JOCOATTM and IPCOATTM devices. ARC's devices are backed by favorable JOCOATTM efficacy and safety clinical data in orthopedic surgical patients (N=4) and positive IPCOATTM data in a safety clinical trial (N=76); and by 7 separate patent families that provide exclusivity for JOCOATTM and IPCOATTM through 2039 and beyond.
About ARC Medical Inc.:
ARC improves surgical patient recovery by preventing internal adhesions.
ARC is a privately held, medical device company focused on preventing surgical adhesions – a large unmet medical need and markets. Surgical adhesions are fibrous bands of scar tissue that form between internal tissues as a result of surgery, causing the tissues to stick together. Internal adhesions are the most common complication of many types of surgeries and can lead to serious medical issues, including chronic pain, immobility, infertility, and small bowel obstruction – often necessitating an expensive procedure to break or cut apart (“release”) the adhesions.
ARC's high molecular weight, polymer-based, liquid medical devices are designed to prevent or reduce adhesions following common surgeries. The company's liquid medical devices are easily and rapidly applied into the surgical site at the end of an arthroscopy, laparoscopy or open laparotomy surgery; and then flow and form a temporary, physical, polymer barrier film that coats the tissues and mechanically prevents adhesions throughout the entire surgical area. ARC's lead medical devices, JOCOATTM and IPCOATTM, are currently in clinical development for use in orthopedic and gynecological & abdominal surgeries, respectively.
Contact:
Contact ARC for more information or to inquire about investment or partnership opportunities at:
Ray Jordan, Chief Corporate Affairs Officer
ARC Medical Inc.
Email: ...
Phone +1-949-245-5432
Chris Springate, Chief Executive Officer
ARC Medical Inc.
Email: ...
Phone: +1-604-222-9577
Visit us on social media:
ARC Medical Inc.
Funding Enables Initiation of JOCOATTM Orthopedic and IPCOATTM Gynecological Clinical Trials
ARC's fundraising reaffirms investor confidence in our JOCOATTM and IPCOATTM liquid medical devices, in development for the prevention of orthopedic and gynecological & abdominal surgical adhesions” - Dr. Chris Springate, CEO of ARC MedicalVANCOUVER, BRITISH COLUMBIA, CANADA, November 19, 2024 /EINPresswire / --ARC Medical Inc. (ARC), a leader in surgical adhesion prevention, today announced the successful completion of the Company's latest financing, securing USD $3 million.“ARC's fundraising reaffirms investor confidence in our JOCOATTM and IPCOATTM liquid medical devices, in clinical development for the prevention of orthopedic and gynecological & abdominal surgical adhesions, respectively,” stated ARC's CEO, Dr. Chris Springate.
Surgical adhesions are the most common complication of many types of surgeries and are abnormal, fibrous bands of scar tissue that form inside the body between tissues.
ARC announced that funds from the financing will support two new clinical trials to further demonstrate the efficacy and safety of JOCOATTM and IPCOATTM:
JOCOATTM Orthopedic Clinical Trial: Led by Prof. Dr. Robert Litchfield, ARC's Chief Medical Officer and an experienced orthopedic surgery principal investigator, the company's JOCOATTM device will be evaluated in a clinical trial with 20 patients undergoing knee surgery for anterior cruciate ligament (ACL) repair.
IPCOATTM Gynecological Clinical Trial: Led by Prof. Dr. Rudy De Wilde, a worldwide key opinion leader in gynecological surgical adhesion reduction, ARC's IPCOATTM device will be evaluated in a clinical trial with 20 patients undergoing gynecological surgery for the treatment of endometriosis.
In addition to the clinical trials, the funding provides additional runway for ARC to continue current discussions towards a Japanese partnership agreement.
Over 11 million patients in the US and 1 million patients in Japan undergo orthopedic, gynecological and abdominal surgeries that may benefit from the use of ARC's JOCOATTM and IPCOATTM devices. ARC's devices are backed by favorable JOCOATTM efficacy and safety clinical data in orthopedic surgical patients (N=4) and positive IPCOATTM data in a safety clinical trial (N=76); and by 7 separate patent families that provide exclusivity for JOCOATTM and IPCOATTM through 2039 and beyond.
About ARC Medical Inc.:
ARC improves surgical patient recovery by preventing internal adhesions.
ARC is a privately held, medical device company focused on preventing surgical adhesions – a large unmet medical need and markets. Surgical adhesions are fibrous bands of scar tissue that form between internal tissues as a result of surgery, causing the tissues to stick together. Internal adhesions are the most common complication of many types of surgeries and can lead to serious medical issues, including chronic pain, immobility, infertility, and small bowel obstruction – often necessitating an expensive procedure to break or cut apart (“release”) the adhesions.
ARC's high molecular weight, polymer-based, liquid medical devices are designed to prevent or reduce adhesions following common surgeries. The company's liquid medical devices are easily and rapidly applied into the surgical site at the end of an arthroscopy, laparoscopy or open laparotomy surgery; and then flow and form a temporary, physical, polymer barrier film that coats the tissues and mechanically prevents adhesions throughout the entire surgical area. ARC's lead medical devices, JOCOATTM and IPCOATTM, are currently in clinical development for use in orthopedic and gynecological & abdominal surgeries, respectively.
Contact:
Contact ARC for more information or to inquire about investment or partnership opportunities at:
Ray Jordan, Chief Corporate Affairs Officer
ARC Medical Inc.
Email: ...
Phone +1-949-245-5432
Chris Springate, Chief Executive Officer
ARC Medical Inc.
Email: ...
Phone: +1-604-222-9577
Visit us on social media:
Ray Jordan
Putnam Insights LLC
+ +1 9492455432
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment